Citigroup Initiates Coverage On Arrowhead Pharma with Neutral Rating, Announces Price Target of $33
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Shawn Egan has initiated coverage on Arrowhead Pharma with a Neutral rating and a price target of $33.
September 19, 2023 | 9:47 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Citigroup has initiated coverage on Arrowhead Pharma with a Neutral rating and a price target of $33.
The initiation of coverage by Citigroup, a major financial institution, is a significant event for Arrowhead Pharma. The Neutral rating suggests that Citigroup does not expect significant price movement in the short term. The price target of $33 provides a benchmark for investors, but it does not necessarily imply a strong upward or downward trend.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100